AZTR News & Events

Azitra announced the issuance of a new U.S. patent protecting ATR-12, the company's lead product candidate. Azitra is advancing ATR-12 in a Phase 1b clinical trial as a treatment for Netherton syndrome, a chronic and potentially fatal skin disease that is estimated to affect approximately 20,000 patients globally. The patent covers microbes that secrete one or more domains of the lympho-epithelial Kazal-type-related inhibitor protein and methods of using these microbes to treat skin diseases, including Netherton's Syndrome.

Azitra Inc trading halted, news pending

Azitra added The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04. ATR-04 is a first-in-class, topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor-associated rash. The multicenter, randomized, double-blind, vehicle-controlled Phase 1/2 clinical study is designed to evaluate the safety and tolerability of topical ATR04-484 for the treatment of EGFRi-associated dermal toxicity affecting the face of adult patients. The key objectives of the study will be to assess the safety and tolerability of topical ATR04-484 and to evaluate early efficacy signals. The study is currently enrolling patients for Cohort 1, which is anticipated to enroll a total of eight patients.